Searched for
KURT STOECKLI
Study suggests similarity between biosimilar GBR 310 and omalizumab: GlenmarkGlenmark Pharma said that results from a study suggests similarity between biosimilar GBR 310 and the reference product omalizumab.- Glenmark, APC Therapeutics ink licensing pact for cancer drugUnder the terms of the agreement, Glenmark will license the product from APC Therapeutics and manage all clinical development, including re...
- Glenmark anti-myeloma drug gets clinical trial nod from USFDAThis is Glenmark's second investigational new drug from its immuno-oncology portfolio to enter clinical trials.
- FDA okays Glenmark's first-in-human study for respiratory drugAccording to IMS sales data for the 12-month period ending February 2017, annual sales of XOLAIR 150 mg injection was approximately $1.7 bi...
- Buy Glenmark Pharma with a target Rs 959 -- Siddharth BhamreBuy Glenmark Pharmaceuticals Ltd. at a price target of Rs 959.0 and a stop loss at Rs 889.0 from entry point
- Kurt Stoeckli to head Glenmark's global research portfolioBased out of Switzerland, Stoeckli will lead Glenmark’s global research portfolio, including biologics (NBEs) and small molecules (NCEs), t...
Load More